An Artemisinin‐Derivative–(NHC)Gold(I) Hybrid with Enhanced Cytotoxicity through Inhibition of NRF2 Transcriptional Activity
- 18 April 2020
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (29) , 12062-12068
Abstract
A family of hybrid complexes combining two biologically active motifs, an artemisinin derivative and a cationic bis(NHC)‐gold(I) unit, has been synthesized. One of these complexes, 2 a, has been analyzed by single‐crystal X‐ray diffraction. 2 a shows strong anticancer activities on a large panel of human cancer cell models (prostate, breast, lung, liver, bladder, bone, acute and chronic myeloid leukemias) with GI50 values in the nm range, together with a high selectivity. An original and distinctive mechanism of action, that is, through inhibition of the redox antioxidant NRF2 transcription factor (strongly associated with aggressiveness and resistance to cancer therapies) has been evidenced. 2 a could remarkably sensitize to sorafenib in HepG2 liver cells, in which dysregulated NRF2 signaling is linked to primary and acquired drug resistance. 2 a also inhibited NF‐κB and HIF transcriptional activities, which are also associated with progression and resistance in cancer. Our findings provide evidence that hybrid (NHC)gold(I) compounds represent a new class of organometallic hybrid molecules that may yield new therapeutic agents.Keywords
All Related Versions
This publication has 60 references indexed in Scilit:
- Toward clinical application of the Keap1–Nrf2 pathwayTrends in Pharmacological Sciences, 2013
- Synthesis, Characterization, and in Vitro Studies of Bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) ComplexesJournal of Medicinal Chemistry, 2012
- Hypoxia-Inducible Factors in Physiology and MedicineCell, 2012
- Inflammation meets cancer, with NF-κB as the matchmakerNature Immunology, 2011
- Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivoCancer Letters, 2010
- Comparison of methods for evaluating drug-drug interactionFrontiers in Bioscience-Elite, 2010
- Artemisinins: their growing importance in medicineTrends in Pharmacological Sciences, 2008
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- β2-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoproteinOncogene, 2001
- Multidrug resistance in haematological malignanciesJournal of Internal Medicine, 2000